



UNITED STATES DEPARTMENT OF COMMERC Patent and Trademark Office

Address: ASSISTANT SECRETARY AND

COMMISSIONER OF PATENT AND TRADEMARKS

Washington, D.C. 20231

TOT GRP ART UNIT FIL FEE REC'D ATTY.DOCKET.NO DRAWINGS IND CLAIMS APPLICATION NUMBER FILING DATE CLAIMS 834 PC8605B 28 1 09/580,791 05/30/2000 1614

Paul H Ginsburg
Pfizer Inc
235 East 42nd Street 20th Floor
New York, NY 10017-5755

RECEIVED

DEC 1 2 2002

TECH CENTER 1600/2900 Date Mailed: 07/21/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Yuhpyng L. Chen, Residence Not Provided;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 08/741,066 10/30/1996 AND A CIP OF 09/254,387 03/04/1999

Foreign Applications

If Required, Foreign Filing License Granted 07/21/2000

DECEIVED

JUL 28 2000

PATENT DEPT. NYC

Title

Corticotropin releasing factor antagonists

Preliminary Class

514

Data entry by: ERRY, RENUKA

Team: OIPE

Date: 07/21/2000



GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the
 Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along
 with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Yuhpyng L. CHEN

Serial No.:

09/580,791

Group No.:

1614

Filed: May 30, 2000

Examiner:

D. Jones

For:

CORTICOTROPIN RELEASING FACTOR ANTAGONISTS

Assistant Commissioner for Patents

Washington, DC 20231

REQUEST FOR CORRECTED FILING RECEIPT

1. Attached is a copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.

There is an error with respect to the following data, which is: RECEIVED [X] incorrectly entered DEC 1 2 2002 and/or **TECH CENTER 1600/2900** [] omitted.

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. 1.8a)

I hereby certify that this correspondence is, on the date shown below, being:

MAILING

deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: November 18, 2002

FACSIMILE

transmitted by facsimile to the Patent and Trademark Office.

Signatu

JOHN RICHARDS

(type or print name of person certifying)

Error in Correct data 1. 1. [] Applicant's name 2. [] Applicant's address 2. 3. [] Title 3. 4. [] Filing Date 4. 5. 5. [] Serial Number 6. [] Foreign/PCT Application Re: 6. 7. **[X]** Other ATTORNEY DOCKET NO. 7. Delete "PC8605B" and Insert -- U-014293-3--Reg. No. 31,053 (Type/or print name of practitioner) Tel. No.: (212) 708-1915 P.O. Address c/o Ladas & Parry 26 West 61 Street RECEIVED New York, NY 10023 DEC 1 2 2002 Customer No. 00140



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Yuhpyng L. CHEN
-----------------------	-----------------

Serial No.:

09/580,791

Group No.:

1614

Filed: May 30, 2000

Examiner:

D. Jones

For:

CORTICOTROPIN RELEASING FACTOR ANTAGONISTS

Attorney Docket No.: U-014293-3

Commissioner of Patents and Trademarks Washington, DC 20231

Sir:

CORRESPONDENCE ADDRESS

DEC 1 2 2002 TECH CENTER 1600/2900

Please direct all communication to: Ladas & Parry 26 West 61st Street New York, New York 10023

Respectfully submitted,

CERTIFICATION UNDER 37 C.F.R. 1/8(a) and 1.10*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

⊠	deposited with the United States Postal Service Patents, Washington, D.C. 20231.	in an envelope add	dressed to the Assistant Commiss	sioner for
	37 C.F.R. 1.8(a)		37 C.F.R. 1.10*	
\boxtimes	with sufficient postage as first class mail.		as "Express Mail Post Office	to Address"
	•		Mailing Label No 7	(mandatory
	TRA	NSMISSION		7 /)
	transmitted by facsimile to the Patent and Trade	mark Office.		
Date:	November 18, 2002	Signa	ture	
		JOHI	N RICHARDS	
		-	of print name of person certifyin	g)

*WARNING:

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).

"Since the filing of correspondence under \S 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.